<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; developed</title>
	<atom:link href="http://www.tapanray.in/tag/developed/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>What A New Microbe Can Man Can’t?</title>
		<link>http://www.tapanray.in/what-a-new-microbe-can-man-cant/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=what-a-new-microbe-can-man-cant</link>
		<comments>http://www.tapanray.in/what-a-new-microbe-can-man-cant/#comments</comments>
		<pubDate>Mon, 23 Mar 2020 00:00:06 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AMR]]></category>
		<category><![CDATA[Antimicrobial]]></category>
		<category><![CDATA[building]]></category>
		<category><![CDATA[Capacity]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[Covid19]]></category>
		<category><![CDATA[developed]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[mankind]]></category>
		<category><![CDATA[microbe]]></category>
		<category><![CDATA[nations]]></category>
		<category><![CDATA[powerful]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[resistance]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[threats]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9923</guid>
		<description><![CDATA[Our world is indeed so fascinating, where mankind is in possession of a predictable lethal power to annihilate fellow citizens of any country or countries – just in minutes or hours or days, as it would decide. Whereas, any sudden &#8230; <a href="http://www.tapanray.in/what-a-new-microbe-can-man-cant/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/what-a-new-microbe-can-man-cant/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Awaiting The Two To Tango: Pharma Innovation And Public Health Interest</title>
		<link>http://www.tapanray.in/awaiting-the-two-to-tango-pharma-innovation-and-public-health-interest/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=awaiting-the-two-to-tango-pharma-innovation-and-public-health-interest</link>
		<comments>http://www.tapanray.in/awaiting-the-two-to-tango-pharma-innovation-and-public-health-interest/#comments</comments>
		<pubDate>Mon, 02 Jan 2017 00:00:28 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Africa]]></category>
		<category><![CDATA[awaiting]]></category>
		<category><![CDATA[countries]]></category>
		<category><![CDATA[developed]]></category>
		<category><![CDATA[Developing]]></category>
		<category><![CDATA[discovery]]></category>
		<category><![CDATA[disease]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[expectancy]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[high]]></category>
		<category><![CDATA[IGWG]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[interest]]></category>
		<category><![CDATA[life]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[NSSO]]></category>
		<category><![CDATA[Open]]></category>
		<category><![CDATA[OSDD]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[pricey]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[source]]></category>
		<category><![CDATA[tango]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[tropical]]></category>
		<category><![CDATA[two]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8029</guid>
		<description><![CDATA[“The rewards for the breakthrough drug discovery must be substantial, but if prices are the only mechanism through which returns on research flow, affordability will be compromised,” articulated an article titled, ‘Pharmaceutical Policy Reform &#8211; Balancing Affordability with Incentives for Innovation’, &#8230; <a href="http://www.tapanray.in/awaiting-the-two-to-tango-pharma-innovation-and-public-health-interest/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/awaiting-the-two-to-tango-pharma-innovation-and-public-health-interest/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Replication of ‘Old Paradigm’ of the developed pharmaceutical markets is unlikely to yield results in the evolving new paradigm of India</title>
		<link>http://www.tapanray.in/replication-of-old-paradigm-of-the-developed-pharmaceutical-markets-is-unlikely-to-yield-results-in-the-evolving-new-paradigm-of-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=replication-of-old-paradigm-of-the-developed-pharmaceutical-markets-is-unlikely-to-yield-results-in-the-evolving-new-paradigm-of-india</link>
		<comments>http://www.tapanray.in/replication-of-old-paradigm-of-the-developed-pharmaceutical-markets-is-unlikely-to-yield-results-in-the-evolving-new-paradigm-of-india/#comments</comments>
		<pubDate>Mon, 03 Sep 2012 00:00:11 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Compulsory Licensing]]></category>
		<category><![CDATA[Counterfeit]]></category>
		<category><![CDATA[developed]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Ethical Marketing]]></category>
		<category><![CDATA[evolving]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[glaxo]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hospital]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[is]]></category>
		<category><![CDATA[kopran]]></category>
		<category><![CDATA[Legal]]></category>
		<category><![CDATA[markets]]></category>
		<category><![CDATA[Medical Diagnostics]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Neutraceutical]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[Old]]></category>
		<category><![CDATA[OPPI]]></category>
		<category><![CDATA[paradigm]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PHC]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[RDP]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Replication]]></category>
		<category><![CDATA[Research & Development]]></category>
		<category><![CDATA[results]]></category>
		<category><![CDATA[sami]]></category>
		<category><![CDATA[Spurious]]></category>
		<category><![CDATA[stakeholders]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[therapeutic]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[Trials]]></category>
		<category><![CDATA[unlikely]]></category>
		<category><![CDATA[yield]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=40</guid>
		<description><![CDATA[“Health leaps out of science and draws nourishment from the society around it” - Gunnar Myrdal (Swedish Nobel Laureate Economist) The success concoction of the global pharmaceutical industry for India, by and large, still remains to be sustained attempts in &#8230; <a href="http://www.tapanray.in/replication-of-old-paradigm-of-the-developed-pharmaceutical-markets-is-unlikely-to-yield-results-in-the-evolving-new-paradigm-of-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/replication-of-old-paradigm-of-the-developed-pharmaceutical-markets-is-unlikely-to-yield-results-in-the-evolving-new-paradigm-of-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
